Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Linfoma de células del manto. Respuesta al tratamiento y pronóstico en 45 paci...
Journal Information
Vol. 147. Issue 1.
Pages 18-21 (July 2016)
Share
Share
Download PDF
More article options
ePub
Visits
18
Vol. 147. Issue 1.
Pages 18-21 (July 2016)
Nota clínica
DOI: 10.1016/j.medcli.2016.03.016
Linfoma de células del manto. Respuesta al tratamiento y pronóstico en 45 pacientes
Mantle cell lymphoma, response to treatment and prognosis in 45 patients
Visits
...
Marc Sorigue
Corresponding author
mc.sorigue@zoho.com
48096mst@comb.cat

Autor para correspondencia.
, Juan-Manuel Sancho, Olga García, Jordi Vila, Miriam Moreno, Josep-Maria Ribera
Servicio de Hematología Clínica, Institut Català d’Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Tabla 1. Características basales según los grupos de tratamiento
Resumen
Fundamento y objetivo

El linfoma de células del manto (LCM) es un linfoma poco frecuente, con recaídas habituales y mal pronóstico. Este estudio analiza la respuesta al tratamiento y el pronóstico en una serie de pacientes con LCM.

Pacientes y método

Estudio retrospectivo de los pacientes con LCM diagnosticados en un centro entre 1996 y 2013. Se dividió la cohorte en función del tratamiento recibido.

Resultados

Se incluyeron 45 pacientes (32 varones) con una edad mediana de 66 años. Veintiún pacientes recibieron quimioterapia o quimioinmunoterapia intensiva (pautas con citarabina a dosis altas), 13 semiintensiva (sin citarabina a dosis altas), 8 no intensiva y 3 no precisaron tratamiento. La respuesta global fue del 85% con tratamiento intensivo y del 77% con semiintensivo. En el análisis multivariable el tratamiento intensivo se asoció a una mayor probabilidad de supervivencia libre de progresión (SLP) y supervivencia global (SG) (hazard ratio de 9,8 [IC 95% 2,7-35,5], p=0,001 para la SLP y 4,5 [1,2-17,8], p=0,03 para la SG).

Conclusiones

En esta serie retrospectiva de pacientes con LCM el tratamiento intensivo se asoció a mejores resultados respecto al resto de las modalidades de tratamiento.

Palabras clave:
Linfoma de células del manto
Dosis altas de citarabina
Pronóstico
Abstract
Background and purpose

Mantle cell lymphoma (MCL) is a rare lymphoproliferative disorder, with frequent relapses and a poor prognosis. This study analyzes response to treatment and prognosis in a series of MCL patients.

Patients and method

Retrospective study of MCL patients diagnosed in a single institution between 1996 and 2013. The cohort was divided according to the treatment received.

Results

Forty-five patients were included (32 male) with a median age of 66 years old. Twenty-one received intensive chemotherapy or chemoimmunotherapy (based on high-dose cytarabine), 13 semi-intensive (without high-dose cytarabine), 8 not intensive and 3 did not require treatment. Overall response rate was 85% in the intensive and 77% in the semi-intensive treatment groups. In multivariate analysis, intensive treatment was correlated with a longer progression-free survival (hazard ratio 9.8 [95% CI 2.7-35.5], P=.001) and overall survival (4.5 [1.2-17.8], P=.03).

Conclusions

In this retrospective series of MCL patients, intensive treatment was correlated with better outcomes than the other treatment modalities.

Keywords:
Mantle cell lymphoma
High-dose cytarabine
Prognosis

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos